Navigation Links
Lilly Provides Statement in Response to Amylin Lawsuit
Date:5/16/2011

gon-like peptide-1 (GLP-1) receptor agonist to be approved by the FDA for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone GLP-1. GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not currently recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis. BYETTA has not been studied in people who have pancreatitis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss (BYETTA is not a weight-loss product). BYETTA was approved in the U.S. in April 2005 and in Europe in November 2006 and has been used by more than 1.8 million patients since its introduction. See important safety information below. Additional information about BYETTA is available at www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection

Based on postmarketing data BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Patients should be observed for signs and symptoms of pancreatitis after initiation or dose escalation of BYETTA. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who have severe kidney problems and should be used with caution in people who have had a kidney transplant. Patients should talk with their healthcare provider if they ha
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly USA, LLC Launches TruAssist for Patients
2. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
3. Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011
4. Amylin Pharmaceuticals Files Suit Against Eli Lilly
5. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
6. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
7. Lilly and Medtronic Announce Drug-Device Collaboration for Parkinsons Disease
8. Lilly Declares Second-Quarter 2011 Dividend
9. Lilly Reports First-Quarter 2011 Results
10. Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency
11. Avant Healthcare Marketing Receives 2010 Lilly Global Sustained Supplier Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Sihuan Pharmaceutical Holdings ... "Company"), a leading pharmaceutical company with the largest ... China,s prescription drug market, today announced ... its subsidiaries (collectively the "Group") for the six ... Financial HighlightsFor the Six months ended 30 ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014  Columbia Laboratories, ... Company"), a provider of pharmaceutical development, clinical trial manufacturing, ... industry, today announced that it will participate at the ... Investment Conference, to be held in New ... conference at 11:15am on September 9, 2014 at the ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver ... on the Fatty Liver Disease clinical trial scenario. This ... clinical trials on Fatty Liver Disease . It ... recruitment status as per the site of trial conduction ... of disease clinical trials by their phase, trial status, ...
Breaking Medicine Technology:Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5
(Date:8/28/2014)... (PRWEB) August 28, 2014 Now in its ... that was started in 2011 by two brain aneurysm survivors. ... much needed awareness, provide education to help increase early detection ... impacted by a brain aneurysm. We hope that you will ... worthy cause at the 4th Annual Step for Hope Run/ ...
(Date:8/28/2014)... MMAR Medical is pleased to announce ... for regular customers to enjoy several perks and benefits ... a wholesale license. It’s a great choice for independent ... others who regularly purchase medical braces but could use ... own active lifestyle or those of your club, group ...
(Date:8/28/2014)... The revenue cycle process touches on ... time a patient books an appointment with a physician’s ... payments for services rendered to the healthcare provider. ... has the RCM process down to a science. Over ... common place in nearly every healthcare facility around the ...
(Date:8/28/2014)... August 28, 2014 UniVoIP, Inc, a ... Segundo, CA, today announced that they have been certified ... Los Angeles Local Small Business Enterprise (Local SBE) Preference ... certified by the state of California and LA county ... Cloud-hosted Telephony Solution to governmental agencies throughout the ...
(Date:8/27/2014)... 2014 Author and orthopedic surgeon William ... on the thrilling adventures of sharp and witty ... is gearing up for a new marketing push in ... novellas , “Prescription: Murder” follows the adventures of ... dodging assassination attempts and thwarting criminals. In the first ...
Breaking Medicine News(10 mins):Health News:Step for Hope and Raise Brain Aneurysm Awareness 2Health News:MMAR Medical Announces Customer Membership Program 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 3Health News:Cloud PBX Provider UniVoIP Gets Certified by the State of California and the County of Los Angeles Under the Local Small Business Enterprise (SBE) Preference Program 2Health News:William H. Simon Launches New Marketing Campaign for Book 2
... - Sunrise Senior Living and Conrad Properties Partner to Redefine Landmark ... Property Exclusively For Seniors ... SRZ ), an operator of more than 450 senior living communities,worldwide, ... 23- story Clayton on the Park hotel and apartments into an,exclusive ...
... entire Texas,Medical Board (TMB) and its officials have been ... Physicians and Surgeons (AAPS). The complaint,filed this week in ... performing its official duties, specifically:, 1. Manipulation of ... Violation of due process;, 4. Breach of privacy; ...
... Virginia, Dec. 21 Echo Healthcare,Acquisition Corp. ("Echo" ... check company, announced at its special meeting of ... Friday, December 28, 2007 for,stockholders to vote on ... ("XLNT") and the related matters set forth in ...
... Pa. and KENILWORTH, N.J., Dec. 21 ,Centocor, ... ) today announced,they have revised their 1998 ... of both REMICADE(R),(infliximab), an anti-tumor necrosis factor ... golimumab, Centocor,s next-generation,human, anti-TNF alpha therapy, which ...
... will ensure consumers, interests are considered, protected, HARRISBURG, ... are protected, acting Insurance Commissioner Joel,Ario today announced that ... part of its review of the proposed consolidation of,Independence ... is to see that consumers would be protected in,any ...
... team says , FRIDAY, Dec. 21 (HealthDay News) -- People with ... a study that adds to growing evidence of a link between ... analyzed leg and torso measurements, as well as blood samples, from ... , The blood samples were checked for levels of four liver ...
Cached Medicine News:Health News:Sunrise to Unveil New Residence for Seniors at Clayton on the Park 2Health News:Doctors' Group Sues Texas Medical Board for Misconduct; Cites Institutional Culture of Retaliation & Intimidation 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 4Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 5Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 2Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 3Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 4Health News:Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross 2Health News:Shorter Legs Might Boost Liver Risks 2
Button shape tip, round serrated handle, dull finish, overall length 130 mm....
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: